BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 346,421 shares of the medical equipment provider's stock after buying an additional 26,462 shares during the period. Charles Schwab Investment Management Inc. owned about 0.75% of BioLife Solutions worth $8,993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in BLFS. State Street Corp boosted its holdings in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after purchasing an additional 95,788 shares during the period. Geode Capital Management LLC lifted its holdings in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock worth $21,107,000 after buying an additional 18,473 shares during the period. Barclays PLC lifted its holdings in shares of BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock worth $1,613,000 after buying an additional 10,803 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of BioLife Solutions by 40.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider's stock worth $487,000 after buying an additional 5,638 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new position in shares of BioLife Solutions during the third quarter valued at $1,018,000. 93.24% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at BioLife Solutions

In other news, CFO Troy Wichterman sold 987 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sarah Aebersold sold 5,632 shares of BioLife Solutions stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $24.96, for a total value of $140,574.72. Following the transaction, the insider now owns 45,860 shares of the company's stock, valued at approximately $1,144,665.60. This represents a 10.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,117 shares of company stock worth $534,442. Company insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BLFS shares. Benchmark reiterated a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. Northland Securities lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. HC Wainwright upped their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. StockNews.com raised BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. Finally, KeyCorp upped their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.86.

BioLife Solutions Stock Down 1.2 %

NASDAQ BLFS traded down $0.32 during trading on Wednesday, hitting $25.50. The company's stock had a trading volume of 183,109 shares, compared to its average volume of 349,335. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The company has a market cap of $1.20 billion, a PE ratio of -24.06 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The business's 50 day simple moving average is $26.38 and its 200-day simple moving average is $25.52.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the firm earned ($0.21) EPS. On average, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.